Middle East & Africa Biosimilars Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)
The Middle East & Africa biosimilars market is expected to grow from US$ 1,190.50 million in 2022 to US$ 6,408.87 million by 2028. It is estimated to grow at a CAGR of 32.4% from 2022 to 2028.
Collaborations for Biosimilars and Clinical Trials is Driving Middle East & Africa Biosimilars Market
Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years. By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding. Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer. There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. The immense potential of the biosimilars market has led to many recent, high-profile collaborations. Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.
Middle East & Africa Biosimilars Market Overview
The Middle East and Africa biosimilar market is segmented into the Saudi Arabia, South Africa, UAE, and Rest of Middle East and Africa. The market growth in this region is attributed due to increasing prevalence of chronic disease, key initiatives by government, and increasing product development are driving the growth of biosimilar market.
According to the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), in 2020, cardiovascular disease is the leading cause of deaths in Saudi Arabia which accounts for 45.7% of all death cases. Further, diabetes is growing in Saudi Arabia due to major lifestyle changes with unhealthy eating habits and sedentary lifestyle. According to IDF, in 2021, the frequency rate of diabetes in Saudi Arabia ranged from 8% to 22%. The major factors for diabetes are obesity, unhealthy lifestyle, increased life expectancy, increased healthcare expenditures, and genetic susceptibility. According to a nationwide survey, in 2022, Saudi Arabia had 5.5% of cardiovascular diseases prevalence. Thus, increasing cardiovascular diseases due to rising diabetes condition in Saudi Arabia is driving the growth of biosimilar market.
Furthermore, the increasing biosimilar product approval in Saudi Arabia is boosting the growth of biosimilar market in Saudi Arabia. For instance, the Saudi Food and Drug Authority (SFDA) has approved Remsima for use in rheumatology indications which is a biosimilar of infliximab manufactured by Celltrion and licensed under a local company, Jazeera Pharmaceutical Industries. Thus, growing chronic diseases conditions and product initiative by key players are driving the growth of biosimilar market in Saudi Arabia
Middle East & Africa Biosimilars Market Revenue and Forecast to 2028 (US$ Million)
Middle East & Africa Biosimilars Market Segmentation
The Middle East & Africa biosimilars market is segmented into disease indication, drug class, route of administration, end user, and country.
Based on disease indication, the biosimilars market is segmented into cancer, diabetes, autoimmune diseases, and other disease indications. The cancer segment held the largest market share in 2022.
The biosimilars market, based on drug class, is segmented into granulocyte colony-stimulating stimulating factors, human growth hormone, insulin, TNF blockers & monoclonal antibodies, erythropoietin-stimulating stimulating agents, and others. The granulocyte colony-stimulating factors segment accounted for the largest share of the market in 2022.
Based on route of administration, the biosimilar market is segmented into intravenous, subcutaneous, and others. The intravenous segment accounted for the largest share of the market in 2022.
The biosimilars market, based on end user, is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment accounted for the largest share of the market in 2022.
Based on country, the Middle East & Africa biosimilars market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the market in 2022.
Amgen Inc; Sanofi SA; Biocon Ltd; Eli Lilly and Co; Sandoz AG; Teva Pharmaceutical Industries Ltd; Pfizer Inc; and Dr. Reddy's Laboratories Ltd are the leading companies operating in the Middle East & Africa biosimilars market.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East & Africa Biosimilars Market – by Disease Indication
1.3.2 Middle East & Africa Biosimilars Market – by Drug class
1.3.3 Middle East & Africa Biosimilars Market – by Route of Administration
1.3.4 Middle East & Africa Biosimilars Market – by End User
1.3.5 Middle East & Africa Biosimilars Market – by Country
2. Middle East & Africa Biosimilars Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Biosimilars Market – Market Landscape
4.1 Overview
4.2 Middle East & Africa PEST Analysis
4.3 Expert’s Opinion
5. Middle East & Africa Biosimilars Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Chronic Diseases
5.1.2 Cost Effectiveness of Biosimilar Drugs
5.1.3 Rising Approvals of Biosimilars
5.2 Market Restraints
5.2.1 High-Cost Involvement and Complexities in Biosimilar Product Manufacturing
5.3 Market Opportunities
5.3.1 Patent Expiry of Blockbuster Biologics
5.4 Future Trend
5.4.1 Collaborations for Biosimilars and Clinical Trials
5.5 Impact analysis
6. Biosimilars Market – Middle East & Africa Analysis
6.1 Middle East & Africa Biosimilars Market Revenue Forecast and Analysis
7. Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – by Disease Indication
7.1 Overview
7.2 Middle East & Africa Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
7.3 Cancer
7.3.1 Overview
7.3.2 Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Diabetes
7.4.1 Overview
7.4.2 Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Autoimmune Diseases
7.5.1 Overview
7.5.2 Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.3 Psoriasis:
7.5.3.1 Overview
7.5.3.2 Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.4 Arthritis:
7.5.4.1 Overview
7.5.4.2 Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.5.5 Others:
7.5.5.1 Overview
7.5.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Others Disease Indications
7.6.1 Overview
7.6.2 Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8. Middle East & Africa Biosimilars Market Analysis and Forecast to 2028 – by Drug Class
8.1 Overview
8.2 Middle East & Africa Biosimilars Market, by Drug class 2021 & 2028 (%)
8.3 Granulocyte colony-stimulating factors
8.3.1 Overview
8.3.2 Granulocyte colony-stimulating factors Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Insulin
8.4.1 Overview
8.4.2 Insulin Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 TNF Blockers and Monoclonal Antibodies
8.5.1 Overview
8.5.2 TNF Blockers and Monoclonal Antibodies Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9. Middle East & Africa Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration
9.1 Overview
9.2 Middle East & Africa Biosimilars Market, by Application 2021 & 2028 (%)
9.3 Intravenous
9.3.1 Overview
9.3.2 Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Subcutaneous
9.4.1 Overview
9.4.2 Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10. Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – by End User
10.1 Overview
10.2 Middle East & Africa Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Homecare
10.5.1 Overview
10.5.2 Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
10.6 Other
10.6.1 Overview
10.6.2 Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
11. Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – Country Analysis
11.1 Overview
11.1.1.1 Saudi Arabia: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 Saudi Arabia: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 Saudi Arabia: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.1.3.1 Saudi Arabia: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.1.4 Saudi Arabia: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.1.5 Saudi Arabia: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.1.6 Saudi Arabia: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 South Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 South Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.2 South Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.2.2.1 South Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.2.3 South Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.2.4 South Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.2.5 South Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 UAE: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 UAE: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.2 UAE: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.3.2.1 UAE: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.3.3 UAE: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.3.4 UAE: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.3.5 UAE: Biosimilar Market, by End User, 2019–2028 (US$ Million)
11.1.1.4 Rest of Middle East and Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.1 Rest of Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.2 Rest of Middle East and Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)
11.1.1.4.2.1 Rest of Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)
11.1.1.4.3 Rest of Middle East and Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)
11.1.1.4.4 Rest of Middle East and Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)
11.1.1.4.5 Rest of Middle East and Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million)
12. Biosimilars Market – Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Biosimilars Market
12.3 Inorganic Growth Strategies
12.3.1 Overview
12.4 Organic Growth Strategies
12.4.1 Overview
13. Company Profiles
13.1 Amgen Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Sanofi SA
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Biocon Ltd
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Eli Lilly and Co
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Sandoz AG
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Pfizer Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms
LIST OF TABLES
Table 1. Comparison Between Different Drug Developments
Table 2. Saudi Arabia Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 3. Saudi Arabia Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 4. Saudi Arabia Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 5. Saudi Arabia Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 6. Saudi Arabia Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 7. South Africa Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 8. South Africa Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 9. South Africa Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 10. South Africa Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 11. South Africa Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 12. UAE Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. UAE Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 14. UAE Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 15. UAE Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 16. UAE Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Middle East and Africa Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Middle East and Africa Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of Middle East and Africa Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)
Table 20. Rest of Middle East and Africa Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Middle East and Africa Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 22. Recent Inorganic Growth Strategies in the Biosimilars Market
Table 23. Recent Organic Growth Strategies in the Biosimilars Market
Table 24. Glossary of Terms
LIST OF FIGURES
Figure 1. Middle East & Africa Biosimilars Market Segmentation
Figure 2. Middle East & Africa Biosimilars Market, by Country
Figure 3. Middle East & Africa Biosimilars Market Overview
Figure 4. Cancer Segment Held Largest Share of Type Segment in Middle East & Africa Biosimilars Market
Figure 5. UAE Expected to Show Remarkable Growth During Forecast Period
Figure 6. Middle East & Africa: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Middle East & Africa Biosimilars Market Impact Analysis of Drivers and Restraints
Figure 9. Middle East & Africa Biosimilars Market – Revenue Forecast and Analysis – 2020–2028
Figure 10. Middle East & Africa Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)
Figure 11. Cancer: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Diabetes: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Autoimmune Diseases: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Psoriasis: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. Arthritis: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Others: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Others Disease Indications: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Middle East & Africa Biosimilars Market, by Drug class 2021 & 2028 (%)
Figure 19. Granulocyte colony-stimulating factors Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. Insulin Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. TNF Blockers and Monoclonal Antibodies Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Others Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. Middle East & Africa Biosimilars Market, by Application 2021 & 2028 (%)
Figure 24. Intravenous: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Subcutaneous: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Others: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Middle East & Africa Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)
Figure 28. Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. Homecare: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Other: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. Middle East and Africa: Biosimilar Market, by Key Country – Revenue (2022) (US$ Million)
Figure 33. Middle East and Africa: Biosimilar Market, by Country, 2021 & 2028 (%)
Figure 34. Saudi Arabia Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 35. South Africa Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 36. UAE Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 37. Rest of Middle East and Africa Biosimilar Market Revenue and Forecast to 2028 (USD Million)
Figure 38. Growth Strategies in the Biosimilars Market
- Amgen Inc
- Sanofi SA
- Biocon Ltd
- Eli Lilly and Co
- Sandoz AG
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc
- Dr. Reddy's Laboratories Ltd
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa biosimilars market
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the biosimilars market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution